Real-time Estimate
Cboe BZX
03:59:45 2024-07-09 pm EDT
|
5-day change
|
1st Jan Change
|
0.506
USD
|
+1.20%
|
|
+4.41%
|
-64.07%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
292.7
|
76.51
|
162.5
|
80.61
|
-
|
Enterprise Value (EV)
1 |
235.9
|
76.51
|
229.9
|
113.5
|
80.81
|
P/E ratio
|
-
|
-0.28
x
|
-2.24
x
|
-1.65
x
|
-2.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.46
x
|
0.07
x
|
0.13
x
|
0.05
x
|
0.05
x
|
EV / Revenue
|
0.37
x
|
0.07
x
|
0.18
x
|
0.07
x
|
0.05
x
|
EV / EBITDA
|
-2.47
x
|
-0.6
x
|
-2.69
x
|
32.9
x
|
3.93
x
|
EV / FCF
|
-
|
-0.57
x
|
-2.95
x
|
7.72
x
|
2.24
x
|
FCF Yield
|
-
|
-175%
|
-33.9%
|
13%
|
44.5%
|
Price to Book
|
-
|
-
|
3.11
x
|
1.11
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
41,579
|
41,579
|
115,242
|
161,225
|
-
|
Reference price
2 |
7.040
|
1.840
|
1.410
|
0.5000
|
0.5000
|
Announcement Date
|
10/21/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
637.4
|
1,050
|
1,266
|
1,522
|
1,735
|
EBITDA
1 |
-
|
-95.49
|
-127.9
|
-85.5
|
3.453
|
20.56
|
EBIT
1 |
-
|
-187.9
|
-1,561
|
-167.9
|
-92.1
|
-82.06
|
Operating Margin
|
-
|
-29.49%
|
-148.73%
|
-13.26%
|
-6.05%
|
-4.73%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-1,560
|
-183.7
|
-113.5
|
-94.83
|
Net income
1 |
-41.07
|
-
|
-270.1
|
-57.77
|
-19.93
|
4.709
|
Net margin
|
-
|
-
|
-25.74%
|
-4.56%
|
-1.31%
|
0.27%
|
EPS
2 |
-0.6200
|
-
|
-6.500
|
-0.6300
|
-0.3033
|
-0.2233
|
Free Cash Flow
1 |
-
|
-
|
-133.8
|
-77.86
|
14.7
|
36
|
FCF margin
|
-
|
-
|
-12.74%
|
-6.15%
|
0.97%
|
2.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
425.75%
|
175.14%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
764.49%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/12/21
|
10/21/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
177.9
|
273.5
|
269.5
|
248.3
|
258.2
|
302.1
|
329.1
|
288.4
|
346.9
|
388.5
|
382.1
|
361.5
|
390.2
|
433.1
|
432.2
|
EBITDA
1 |
-43.05
|
-18.93
|
-28.6
|
-40.31
|
-40.1
|
-19.13
|
0.217
|
-22.33
|
-44.26
|
-19.77
|
-1.676
|
11.18
|
13.77
|
-16.22
|
10.78
|
EBIT
1 |
-127.4
|
-52.17
|
-912.2
|
-60.01
|
-536.5
|
-48.82
|
-21.03
|
-33.82
|
-64.26
|
-43.83
|
-24.61
|
-12.57
|
-11.07
|
-
|
-
|
Operating Margin
|
-71.63%
|
-19.07%
|
-338.53%
|
-24.17%
|
-207.78%
|
-16.16%
|
-6.39%
|
-11.73%
|
-18.53%
|
-11.28%
|
-6.44%
|
-3.48%
|
-2.84%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-65.33
|
-530.5
|
-52.16
|
-27.36
|
-36.88
|
-67.34
|
-47.53
|
-30.71
|
-17.94
|
-17.51
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-11.17
|
-94
|
-9.199
|
-9.816
|
-13.3
|
-25.46
|
-18.7
|
-0.1115
|
-0.042
|
-1.077
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-4.5%
|
-36.41%
|
-3.05%
|
-2.98%
|
-4.61%
|
-7.34%
|
-4.81%
|
-0.03%
|
-0.01%
|
-0.28%
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.2700
|
-2.260
|
-0.2200
|
-0.0900
|
-0.1200
|
-0.2200
|
-0.1600
|
-0.0967
|
-0.0367
|
-0.0300
|
-0.1300
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/21/22
|
10/21/22
|
10/20/22
|
11/14/22
|
3/31/23
|
5/10/23
|
8/7/23
|
11/8/23
|
3/28/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
67.4
|
32.9
|
0.2
|
Net Cash position
1 |
-
|
56.9
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.7881
x
|
9.529
x
|
0.00973
x
|
Free Cash Flow
1 |
-
|
-
|
-134
|
-77.9
|
14.7
|
36
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
0.4500
|
0.4500
|
0.4000
|
Cash Flow per Share
2 |
-
|
-1.680
|
-3.030
|
-0.2600
|
0.0500
|
0.1000
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/12/21
|
10/21/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Average target price
2.7
USD Spread / Average Target +440.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -64.07% | 80.61M | | +16.79% | 44.63B | | +42.66% | 40.46B | | -8.14% | 38.07B | | +32.98% | 32.27B | | -7.10% | 27.3B | | +14.33% | 26.53B | | +47.37% | 14.06B | | +33.64% | 12.54B | | -8.15% | 11.28B |
Other Biotechnology & Medical Research
|